Welcome to another busy day in pharma. While the clear skies and refreshing breezes outside the Pharmalot campus set a pleasant tone, our to-do list remains packed. Here’s what’s making headlines today.
RFK Jr. Launches Initiatives to Reduce Antidepressant Dependence
U.S. Health and Human Services Secretary Robert F. Kennedy Jr. unveiled several initiatives aimed at curbing the prescription of selective serotonin reuptake inhibitors (SSRIs), the most widely prescribed class of antidepressants. Kennedy has previously described SSRIs as exceptionally difficult to quit.
The new measures include:
- Enhanced clinician training programs
- Revised reimbursement mechanisms
- Updated clinical guidelines
These changes encourage healthcare providers to help patients taper off medications and explore non-pharmaceutical alternatives such as therapy, nutrition, and exercise. SSRIs, including Zoloft, Lexapro, Paxil, and Prozac, are first-line treatments for depression and anxiety.
According to recent data, 16.7% of U.S. adults (approximately one in six) reported taking an SSRI in 2026.
Johnson & Johnson Advances IBD Drug Combination to Late-Stage Trials
A closely watched therapy developed by Johnson & Johnson (J&J) failed to demonstrate a statistically significant improvement in patients with inflammatory bowel disease (IBD). Despite this setback, the company intends to progress the drug into late-stage testing, focusing on a specific subgroup of patients.
On Tuesday, trial investigators presented findings from a study evaluating the combination of Tremfya and Simponi in preventing the immune system from attacking healthy tissues in the digestive tract. The combined therapy was tested in two Phase 2b clinical trials covering both major forms of IBD: ulcerative colitis and Crohn’s disease.
While the combination performed better than either drug alone, it did not meet the primary endpoint of achieving clinical remission.
Continue to STAT+ for the full story.
Related articles
FDA Drug Center Acting Director Tracy Beth Høeg Departs Amid Leadership Changes
WASHINGTON — The acting director of the Food and Drug Administration’s drug center, Tracy Beth Høeg, is leaving the agency, according to three sources...
Major Study Finds No Link Between Antidepressants in Pregnancy and Autism or ADHD in Children
A large study found no link between SSRI use before or during pregnancy and neurodevelopmental disorders in children. Ekaterina Goncharova/Getty Image...
Robert F. Kennedy Jr. Balances Vaccine Skepticism with Ohio Outreach Tour
Here in Washington, we’ve been hearing about tensions between the White House and one of its most controversial — but, at least in some circles, most...
Kratom Use Surges in the US: Rising Addiction and Mental Health Concerns
A national study of kratom use in the US found rising popularity among young adults, and it is linked to addiction and mental health issues, according...
STAT+ Roundup: New Hires and Promotions in Biotech and Pharma
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others....
UK Political Shake-Up Could Reshape Global Drug Pricing Policies
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Congrats on...
U.S. Pressures Germany on Drug Prices Amid FDA Restructuring Concerns
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about we...
Minnesota Lawmaker Proposes Redirecting Healthcare Tax to Boost Hospital Charity Care
Minnesota lawmakers are wrestling with how to sustain the state’s financially distressed hospitals while patients confront growing medical debt. One M...